Safety and efficacy of biweekly cetuximab based chemotherapy for patients with metastatic colorectal cancer

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter J. Zekri
Citation Annals of Oncology (2016) 27 (2): 86-101. 10.1093/annonc/mdw201
Authors J. Zekri1, K. Farag2, R. Haggag3
  • 1Alfaisal University, Jeddah, Saudi Arabia, /
  • 2King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia, /
  • 3Zagazig University, Zagazig, Egypt, /

Abstract

Cetuximab was administered weekly in registration clinical trials. Biweekly administration is more convenient when combining cetuximab with biweekly chemotherapy in patients with metastatic colorectal cancer (mCRC). Objective: The aim of this study is to evaluate safety and efficacy of biweekly cetuximab at a dose of 500 mg/m2 with chemotherapy in routine clinical practice.